RFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICSRFK JR. ANNOUNCEMENT · FEB 27 2026 · 14 PEPTIDES RETURN TO CATEGORY 1DATABASE UPDATED · 847 NEW PUBMED CITATIONS THIS WEEKRETATRUTIDE · GRADE B EVIDENCE · 4 NEW CLINICAL TRIALSCOA SCANS · 2,341 BATCHES VERIFIED BY COMMUNITY THIS MONTHFDA ENFORCEMENT · PEPTIDE SCIENCES SHUTDOWN · MAR 2026GLP-1 DIRECTORY · 47 VERIFIED TELEHEALTH CLINICS
Home/Compounds/Tirzepatide
GLP-1 agonistFDA approvedRx required

Tirzepatide

Also known as: Mounjaro · Zepbound
Brands: Mounjaro · Zepbound

Dual GIP/GLP-1 receptor agonist for type 2 diabetes and weight management with superior efficacy.

A
Grade A
Multiple human RCTs
Human studies80
PubMed citations0
Typical dose2.5 mg – 15 mg
Routesubcutaneous
Regulatory (US)FDA approved · Rx
Last verifiedyesterday
TL;DR · 30-second summary
  • Up to 22.5% body weight reduction in SURMOUNT-1
  • Superior to semaglutide 1mg in SURPASS-2
  • 91% of patients achieved >5% weight loss
  • Significant improvements in cardiometabolic markers

Mechanism of action

First-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, providing enhanced metabolic effects through dual incretin pathway activation.

Evidence summary

80
Human studies
0
PubMed citations
0
Clinical trials
A
Evidence grade

SURPASS and SURMOUNT trials demonstrated unprecedented weight loss (up to 22.5%) and HbA1c reduction. Shows superiority over semaglutide in head-to-head trials.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Dose range
2.5 mg – 15 mg

Start at 2.5mg weekly for 4 weeks, then escalate every 4 weeks. Maintenance: 5-15mg weekly.

Administration routes
subcutaneous

Side effects & safety

Reported side effects
NauseaDiarrheaDecreased appetiteVomitingConstipationDyspepsia
Contraindications
  • Personal/family history of medullary thyroid carcinoma
  • MEN2 syndrome
  • Pregnancy

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/17/2026

Citations

No citations indexed yet.